Through an integrated screening system, the authors catalog ALK and ROS1 fusions in lung cancer and identify a new class of fusions involving KIF5B and RET that may represent new therapeutic targets in adenocarcinoma.
- Kengo Takeuchi
- Manabu Soda
- Yuichi Ishikawa